The exchangeable apolipoproteins play a critical role in plasma lipoprotein metabolism.
As many as 11 different exchangeable apolipoproteins have been identified and characterized from human plasma and these generally possess a common structural motif: the amphipathic α-helix (1) . Given their fundamental and essential role in plasma lipoprotein metabolism, it is generally recognized that aberrations in exchangeable apolipoprotein concentration or structure can lead to dyslipidemia and premature atherosclerosis. For example, using gene disruption techniques, it has been shown that a deficiency in apoE leads to severe hypercholesterolemia and premature atherosclerosis (2, 3) . On the other hand, apoA-I and apoA-IV transgenic mice were protected from diet-induced atherosclerosis (4, 5) .
Recently, a new member of the exchangeable apolipoprotein family was discovered. In a comparative genomics study designed to identify evolutionary conserved sequences with potential function, Pennacchio et al. (6) To evaluate the physiological role of apoA-V Pennacchio et al. (6) generated transgenic mice that over-express human apoA-V protein as well as mice lacking apoA-V using gene disruption techniques. Profound effects were observed in both transgenic and knockout mice.
ApoA-V transgenic mice displayed a 3-fold lower plasma triacylglycerol (TG) level compared to control littermates. By contrast, apoA-V knockout mice revealed a 4-fold higher plasma TG compared to controls. Levels of very low-density lipoprotein (VLDL) particles were increased in the homozygous knockout mice and decreased in the transgenic mice, compared to controls. In the heterozygous knockout mouse VLDL levels were intermediate between the homozygous knockout and control mouse. Using cDNA subtraction techniques van der Vliet et al (7) demonstrated that mRNA encoding a novel gene, identified as apoA-V, was up-regulated following partial hepatectomy. ApoA-V protein was secreted by the liver and was transported primarily on large high density lipoprotein (HDL). In subsequent adenoviral-mediated transfection experiments van der Vliet et al. (8) induced a 20-fold increase in apoA-V plasma concentrations that resulted in a 70% decrease in TG levels.
The association of apoA-V with HDL in the mouse and rat suggests that the protein possesses lipid binding properties similar to that of other exchangeable apolipoproteins. Its HDL association may also be important in interaction of the protein with membrane lipids where it may have a role in cholesterol efflux or facilitated lipid exchange reactions. This HDLassociation might also be linked with an ability of apoA-V to activate lecithin:cholesterol acyltransferase (LCAT) since both apoA-I and apoA-IV have this capability. To investigate apoA-V structure and function relations, we constructed a plasmid vector for expression of 6 recombinant human apoA-V in bacteria. As reported here, recombinant apoA-V possesses hallmark features of an exchangeable apolipoprotein yet possesses unique characteristics that may ultimately be important to the mechanism whereby it modulates plasma lipid homeostasis.
Experimental Procedures
ApoA-V/ pET plasmid vector. The coding sequence of human apoA-V (a kind gift of Drs. Eddy Rubin and Len Pennacchio) was amplified using synthetic oligonucleotide primers and inserted into the pBluescript KS(+) vector (Stratagene, La Jolla, CA). Manipulations of the DNA sequence were performed in this plasmid, which was propagated in E. coli DH5α cells. DNA sequencing was performed to verify that no unwanted mutations occurred during the process of plasmid vector construction. For protein expression the apoA-V cDNA was subcloned into the pET 20b+ plasmid (Novagen, Madison, WI) to yield the pET/A-V vector. Mouse plasma samples were obtained from Dr. Len Pennacchio (Lawrence Berkeley Laboratories).
Expression and purification of recombinant apoA-V. ApoA-V expression and purification were performed according to Ryan et al. (9) with some modification. Briefly, E. coli BL21(DE3)pLysS cells bearing the pET/A-V plasmid were cultured in 500 ml NCZYM media (+50 µg/ml ampicillin) at 37 °C. When the culture OD 600 reached 0.6, apoA-V synthesis was induced by the addition of isopropylthiogalactopyranoside to a final concentration of 0.5 mM. Substrate (Pierce Chemical Company) in which both reagents were diluted by adding 0.5 ml in 9 ml of dH 2 0. The substrate was incubated for 2 -5 min at room temperature and exposed to CLXposure Film (Pierce Chemical Co.) for 60 sec. Film was developed using a Kodak M35A X-OMAT processor.
Analytical procedures. Protein concentrations were determined using the bicinchoninic acid assay (Pierce Chemical Co.) using bovine serum albumin as standard. SDS-PAGE was performed on 4 -20 % acrylamide slab gels run at 30 mA constant current for 1.5 h. Gels were stained with Coomassie Brilliant Blue R-250 and the relative mobility of protein samples compared to that of known standards (Bio-Rad low MW standards). ApoA-V solubility studies were conducted at various pH values employing 50 mM sodium citrate, sodium phosphate or Tris (plus 150 mM NaCl) within the range of pH 2.5 to 9.5.
Circular dichroism spectroscopy. Far UV circular dichroism (CD) measurements were performed on a Jasco J-720 spectropolarimeter using Jasco J-700 Hardware Manager Software (v 1.10.00) on a Pentium computer (Win98). The spectropolarimeter was routinely calibrated using a 0.06% (w/v) aqueous solution of ammonium d-10 camphor sulphonate at 290.5 nm. Scan were performed using a 0.02 cm path length cuvette and a protein concentration of 21.5 µM. The sample chamber was maintained at a constant 25 °C using a Lauda RM6 refrigerated recirculating water bath. Temperature denaturation scans were performed using a 0.10 cm path length cuvette in a Jasco Peltier-type thermostatic cell holder and a protein concentration of 6.64 µM. All protein samples were dissolved in 50 mM sodium citrate, pH 3.0. The concentrations of apoA-V stock solutions were determined hydrodynamically by fringe count in a Beckman XLI analytical ultracentrifuge according to Babul and Stellwagen (10) . Baseline correction, noise reduction and ellipticity calculations for the scans were done using Jasco J-700 for Windows Analytical Ultracentrifugation. Sedimentation equilibrium experiments were conducted at 30 °C in a Beckman XL-I Analytical Ultracentrifuge using interference optics, as described by Laue and Stafford (12) . Aliquots (110 ul) of sample solution were loaded into 6-sector CFE sample cells, allowing 3 concentrations of sample to be run simultaneously. Runs were performed at a minimum of 2 different speeds and each speed was maintained until there was no significant difference in r 2 /2 versus absorbance scans taken 2 hours apart to ensure that equilibrium was achieved. The sedimentation equilibrium data was evaluated using the NONLIN program, which incorporates a nonlinear least-squares curve-fitting algorithm described by Johnson et al. (13) .
This program allows the analysis of both single and multiple data files. Data can be fit to either a single ideal species model or models containing up to four associating species, depending on which parameters are permitted to vary during the fitting routine. The protein's partial specific volume and the solvent density were estimated using the SEDNTERP program, which incorporates calculations detailed by Laue et al. (14) .
ApoA-V interaction with phospholipid. Bilayer vesicles of dimyristoylphosphatidylcholine
(DMPC) were prepared by extrusion as described elsewhere (15) in 50 mM sodium citrate, 150 mM NaCl, pH 3.0. Vesicles were incubated with apoA-V (1:1 w/w) at 24 °C for 16 h.
Following incubation the sample was adjusted to 1.31 g/ml by the additional of solid KBr (2.5 ml final volume), transferred to a 5.1 ml centrifuge tube, overlayered with 2.5 ml saline and centrifuged at 275,000 g for 5 h in a Beckman VTi 65.2 rotor. The tube contents were fractionated (0.5 ml) and those containing phospholipid and protein were combined, dialyzed into phosphate buffered saline and stored at 4 °C. The size distribution of DMPC-apoA-V complexes was evaluated by non-denaturing gradient PAGE as described by Nichols et al. (16) .
Morphology of complexes was determined by negative stain electron microscopy as previously described (17) .
Lecithin:cholesterol acyltransferase activity assays. The ability of apoA-V to activate lecithin:cholesterol acyltransferase (LCAT) was examined using recombinant LCAT obtained from CHO-K1 cells stably transfected with human LCAT cDNA (a kind gift of Dr. John Parks).
Cholesterol esterification was assessed using the exogenous substrate procedure described by
Chen and Albers (18) . Proteoliposomes composed of either apoA-V (or apoA-I) were prepared using egg-yolk phosphatidylcholine (PC) and unesterified cholesterol (1:250:12.5, mole ratios, respectively) containing trace amounts of [ 14 C]cholesterol as previously described (19) .
Proteoliposomes were exposed to increasing concentrations (0.2-1.0 µg) of purified LCAT protein to measure initial reaction rates in incubation mixtures containing human serum albumin (0.5 %), β-mercaptoethanol (5 mM), and Tris (20 mM) buffered saline EDTA (2.7 mM).
Incubations were performed at 37 °C for 0. CD spectrum of apoA-V. A far UV CD spectrum of apoA-V is depicted in Figure 3 . The spectrum reveals molar ellipticity minima at 208 nm and 222 nm, indicative of the presence of α-helix secondary structure. Deconvolution of the spectrum with the Contin program of Provencher and Glöckner (11) indicated that, at pH 3, apoA-V is comprised of 32 % a-helix, 33 % ß-sheet, 16 ß-turn and 18 % random coil. Thus, unlike most members of the exchangeable apolipoprotein family, apoA-V displays significant amounts of ß structure.
ApoA-V stability properties. To assess its stability properties in solution, the effect of temperature on the ellipticity of apoA-V was determined (Figure 4) . As the temperature was increased from 5 to 37 °C a small decrease in negative ellipticity was noted. However, above 37°C
, there was a much sharper temperature dependent decrease in molar ellipticity, with nearly complete loss of structure occurring at 60 °C. Between 60 °C and 85 °C, further losses in molar ellipticity were small. The general features of the temperature melt profile are consistent with a single native -> unfolded transition with a midpoint of 47.1 °C. To evaluate the reversibility of temperature induced unfolding of apoA-V, CD spectral scans were obtained before, during and after a temperature melt ( Figure 5) . The results obtained revealed that, although apoA-V recovers from the melt, it is unable to regain 100% of the molar ellipticity present in unheated apoA-V.
ApoA-V self-association. To investigate apoA-V self association properties, sedimentation equilibrium experiments were performed in 50 mM sodium citrate, pH 3.0 at speeds of 8,000 and 12,000 rpm and loading concentrations of 1.50, 2.70, and 5.88 mg/ml. A significant dependence on rotor speed and loading concentration was observed in the calculated apparent average molecular weights, ranging from 330,000 at 8,000 rpm to 68,000 at 12,000 rpm. It was not possible to obtain a good fit to any of the self-association models when fitting all of the data sets globally using the NonLin program. Under these conditions we conclude that apoA-V undergoes non-specific aggregation at the concentrations used in these experiments. Further runs were performed with the inclusion of different concentrations of NaCl added to the buffer with no effect on the association / aggregation phenomenon. LCAT activation and cholesterol efflux properties of apoA-V. To evaluate the ability of apoA-V to serve as an activator of LCAT, purified apoA-V was used to prepare a proteoliposome substrate that was exposed to physiological concentrations of purified LCAT. Compared with apoA-I, apoA-V was a poor activator of LCAT, where activity was 8.5±1.8% (n=3) that of apoA-I. In studies of apolipoprotein mediated cholesterol efflux, apoA-I was used as a positive control. ApoA-I is known to stimulate the efflux of cholesterol from cells through interaction with the ABCA-1 transporter. Up-regulation of ABCA1 by cAMP maximizes cholesterol efflux.
ApoA-V binding to phospholipid. Upon incubation with bilayer vesicles of DMPC
As shown in Figure 7 , apoA-V-mediated cholesterol efflux was unaffected by cAMP treatment of the cells and efflux levels were low. ApoA-I, on the other hand, shows the expected increase in cellular cholesterol efflux in the presence of cAMP. The data suggest that cholesterol efflux to apoA-V occurs through an ABCA1-independent mechanism.
Discussion
With the advent of the human genome project and the ability to compare large tracts of sequence across species, new opportunities for discovery of potentially important gene products
exists. An excellent example of this concept emerged with the discovery of a previously unknown member of the exchangeable apolipoprotein family, apoA-V. Whereas genetic studies illustrate the important role played by apoA-V in plasma lipid metabolism, particularly TG metabolism (6, 22, 23) , questions remain about the mechanism whereby apoA-V exerts its biological effects. The goal of determining how apoA-V influences plasma TG levels requires additional knowledge of the protein itself. In fact, previously, human apoA-V has not been isolated and little is known of its structure, stability, lipid interaction properties or potential regulatory effects.
Human apoA-V is synthesized with a cleavable signal peptide, comprising the first 23 amino acids of the protein sequence. This signal sequence directs the protein toward a secretory pathway, resulting in the appearance of apoA-V in plasma. To improve our understanding of apoA-V structure and function relationships, we created a vector construct for expression of human apoA-V in E. coli. Following optimization of the expression and purification protocol, yields of recombinant apoA-V in the range of 3-5 mg/L bacterial culture were obtained.
Recombinant apoA-V was used as an antigen to generate polyclonal antibodies in a goat. In characterization studies it was shown that goat anti human apoA-V IgG is specific for apoA-V and thus, will likely be useful in future studies designed to quantitate apoA-V levels in human plasma samples and correlate these with TG levels. Whereas preliminary studies with human serum revealed specific reactivity against apoA-V, the present anti human apoA-V IgG did not detect mouse apoA-V (Figure 2 , wild type mouse serum lane), suggesting either a lack of epitope conservation or the amounts of apoA-V present are below the limits of detection.
In studies of apoA-V properties, results obtained indicate the lipid-free protein is poorly soluble between the pH limits 3.5 and 9 (at concentration > 0.1 mg/ml). This solution behavior
suggests human apoA-V may exist in association with lipoproteins in the plasma compartment, consistent with its observed plasma distribution in animal models (6, 7) . Based on the fact that apoA-V is a member of the apoA-I/CIII/A-IV gene family whose protein products belong to the exchangeable apolipoprotein family, studies were conducted to characterize apoA-V in the lipid- (24, 25) . In a similar manner, apoA-V self associates in the absence of lipid. As with other apolipoproteins, this may be a mechanism to sequester lipid-binding sites on the protein from exposure to the aqueous milieu. At present it is unknown which regions of apoA-V are responsible for self-association or lipid interaction. In the case of other exchangeable apolipoproteins, such as apoE, lipid interaction induces a conformational change in the protein wherein hydrophobic sites in the protein are exposed to the lipid surface (26) . The present bacterial expression system is ideally suited for experiments designed to dissect which portions of apoA-V that are responsible for self-association and lipid interaction and these studies are in progress.
In the case of human apoA-I or insect apolipophorin III (27) , it has been proposed that lipid interaction is facilitated by adoption of a loosely folded conformation in buffer. Secondary structure elements in both these proteins are stabilized by lipid association, and this may represent a driving force for their intrinsic lipid surface seeking property. Apolipophorin III displays a temperature induced denaturation transition midpoint of 52 °C (28) while the corresponding value for apoA-I is 54 °C (29) . Thermal denaturation experiments with apoA-V revealed a transition midpoint of 47.1 °C, consistent with a loosely folded structure in solution.
Unlike human apoA-I or insect apolipophorin III, apoA-V was unable to fully recover 100 % of its secondary structure elements following temperature-induced denaturation. Thus, apoA-V may possess a more complex tertiary fold, a portion of which is irreversibly altered, upon exposure to elevated temperature. At present it is not known if similar results will be observed with chaotrope-induced unfolding of apoA-V. In light of the fact that guanidine HCl exposure is employed in the protocol used for isolation of recombinant apoA-V, detailed characterization of the ability of apoA-V to recover a fully native conformation following such perturbations will be important to understand the biological role of this protein.
The physico-chemical properties of lipid-free apoA-V suggest that the protein has lipidbinding activity. This was indeed demonstrated by apoA-V's ability to form lipid-protein complexes with DMPC. The complexes are similar to those formed with other exchangebable apolipoproteins and suggest that apoA-V binds to the lipid surface of lipoproteins, particularly HDL (7). Because apoA-V is transported on HDL and has structural similarity to other apolipoproteins such as apoA-IV and apoA-I that are known activators of LCAT, it is conceivable that it can serve to activate this enzyme. As reported herein, however, it is evident that this is not the case, suggesting that the structural motif required for LCAT activation is not present in this protein.
One of the characteristics of exchangeable apolipoproteins, including apoA-I and apoA-IV, is the ability to stimulate the efflux of cholesterol from cells via the ABCA-1 transporter.
However, the present study indicates that this is not the case for apoA-V. By contrast, apoA-V recruits low levels of cholesterol from cells, apparently by an ABCA1 independent mechanism.
Thus, apoA-V appears to have detergent-like properties that allow it to remove membrane lipids in a non-specific manner.
The fact that apoA-V is present in very low concentrations in plasma leaves open the question as to its role in lipid metabolism, despite convincing studies in mice that show a correlation between apoA-V and TG levels. The availability of a recombinant apoA-V and a specific antibody will be useful for future studies in correlating apoA-V and TG levels in mice 20 and humans and by allowing one to assess how apoA-V functions to modulate TG levels. In summary, we have developed a bacterial expression system for production of milligram quantities of human apoA-V. The recombinant protein was isolated and characterized in terms of its solution properties, secondary structure content and thermal stability. In addition, we have generated an antibody directed against apoA-V that provides a potentially useful reagent for detection and quantification of apoA-V. Given the existing correlation between apoA-V and plasma TG in mouse models (6, 8) , human populations studies designed to assess the significance of the correlation between apoA-V concentrations and plasma TG are possible. Because of the strong correlation between elevated plasma TG and cardiovascular disease, knowledge of how apoA-V modulates plasma TG levels may be of therapeutic significance. 
